WO1990015065A1
(en)
*
|
1989-06-05 |
1990-12-13 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides and methods for preparing the same
|
US5256775A
(en)
*
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
CA2029273A1
(en)
*
|
1989-12-04 |
1991-06-05 |
Christine L. Brakel |
Modified nucleotide compounds
|
US5872232A
(en)
*
|
1990-01-11 |
1999-02-16 |
Isis Pharmaceuticals Inc. |
2'-O-modified oligonucleotides
|
US5623065A
(en)
*
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US5149797A
(en)
*
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
WO1991013080A1
(en)
*
|
1990-02-20 |
1991-09-05 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
PT98562B
(pt)
*
|
1990-08-03 |
1999-01-29 |
Sanofi Sa |
Processo para a preparacao de composicoes que compreendem sequencias de nucleo-sidos com cerca de 6 a cerca de 200 bases resistentes a nucleases
|
CA2102804A1
(en)
*
|
1991-05-10 |
1992-11-11 |
Sudhir Agrawal |
3'-end blocked oligonucleotides
|
US7015315B1
(en)
*
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US5965722A
(en)
*
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
US5792608A
(en)
*
|
1991-12-12 |
1998-08-11 |
Gilead Sciences, Inc. |
Nuclease stable and binding competent oligomers and methods for their use
|
US5856455A
(en)
*
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
US20070032446A1
(en)
*
|
1991-12-24 |
2007-02-08 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
EP0618925B2
(de)
*
|
1991-12-24 |
2012-04-18 |
Isis Pharmaceuticals, Inc. |
Antisense oligonukleotide
|
EP0644889A4
(de)
*
|
1991-12-24 |
1996-01-10 |
Isis Pharmaceuticals Inc |
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR MODULATION VON-g(b)-AMYLOID.
|
US5434257A
(en)
*
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
TW244371B
(de)
*
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
US5523389A
(en)
*
|
1992-09-29 |
1996-06-04 |
Isis Pharmaceuticals, Inc. |
Inhibitors of human immunodeficiency virus
|
IL105244A
(en)
*
|
1993-03-31 |
2003-07-31 |
Dpharm Ltd |
Prodrugs with enhanced penetration into cells
|
US6413949B1
(en)
*
|
1995-06-07 |
2002-07-02 |
D-Pharm, Ltd. |
Prodrugs with enhanced penetration into cells
|
AU692816B2
(en)
*
|
1993-07-19 |
1998-06-18 |
Gen-Probe Incorporated |
Oligonucleotide screening assay
|
CA2170869C
(en)
|
1993-09-03 |
1999-09-14 |
Phillip Dan Cook |
Amine-derivatized nucleosides and oligonucleosides
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US6313106B1
(en)
|
1995-06-07 |
2001-11-06 |
D-Pharm Ltd. |
Phospholipid derivatives of valproic acid and mixtures thereof
|
GB9518864D0
(en)
|
1995-09-14 |
1995-11-15 |
Cambridge Res & Innovation |
Oligonucleotides and their uses
|
US5998203A
(en)
*
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
US7070962B1
(en)
|
1996-02-01 |
2006-07-04 |
Aventis Pharmaceuticals Inc. |
Positive controls in polynucleotide amplification
|
JP2000513571A
(ja)
|
1996-06-05 |
2000-10-17 |
カイロン コーポレイション |
Dp.75をコードするdnaおよびその使用のための工程
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
*
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US20040161777A1
(en)
*
|
1996-06-06 |
2004-08-19 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US5849902A
(en)
*
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
US5989912A
(en)
|
1996-11-21 |
1999-11-23 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
US5885834A
(en)
*
|
1996-09-30 |
1999-03-23 |
Epstein; Paul M. |
Antisense oligodeoxynucleotide against phosphodiesterase
|
DE69834038D1
(de)
|
1997-07-01 |
2006-05-18 |
Isis Pharmaceutical Inc |
Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
|
AU8512598A
(en)
*
|
1997-07-25 |
1999-02-16 |
Hybridon, Inc. |
Oligonuclotides having 3' terminal stereospecific phosphorothioates
|
AU770896C
(en)
*
|
1998-09-29 |
2006-09-07 |
Gamida Cell Ltd. |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
US7090975B2
(en)
|
1998-03-13 |
2006-08-15 |
Promega Corporation |
Pyrophosphorolysis and incorporation of nucleotide method for nucleic acid detection
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US7321828B2
(en)
|
1998-04-13 |
2008-01-22 |
Isis Pharmaceuticals, Inc. |
System of components for preparing oligonucleotides
|
AU3751299A
(en)
*
|
1998-04-20 |
1999-11-08 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
EP1080226A4
(de)
*
|
1998-05-21 |
2004-04-21 |
Isis Pharmaceuticals Inc |
Zusammensetzungen und methoden zur topischen verabreichung von oligonukleotiden
|
CA2329130A1
(en)
*
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
ATE354675T1
(de)
*
|
1998-12-02 |
2007-03-15 |
Adnexus Therapeutics Inc |
Dna-protein fusionen sowie anwendungen derselben
|
US6358712B1
(en)
|
1999-01-05 |
2002-03-19 |
Trustee Of Boston University |
Ordered gene assembly
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
JP2002541822A
(ja)
*
|
1999-04-14 |
2002-12-10 |
エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント |
組織特異的および病原体特異的毒性物質ならびにリボザイム
|
JP3513068B2
(ja)
*
|
1999-05-12 |
2004-03-31 |
浜松ホトニクス株式会社 |
生細胞の細胞質内標的核酸を検出する方法
|
WO2000070039A1
(en)
*
|
1999-05-17 |
2000-11-23 |
Mcgill University |
METHOD FOR SUBTRACTING cDNAs BY SUPPRESSING THE SYNTHESIS OF SPECIFICALLY TARGETED mRNAs
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US20030190644A1
(en)
|
1999-10-13 |
2003-10-09 |
Andreas Braun |
Methods for generating databases and databases for identifying polymorphic genetic markers
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US6958214B2
(en)
|
2000-07-10 |
2005-10-25 |
Sequenom, Inc. |
Polymorphic kinase anchor proteins and nucleic acids encoding the same
|
GB0021303D0
(en)
*
|
2000-08-30 |
2000-10-18 |
Medinnova Sf |
Use
|
WO2002059337A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Georgetown University School Of Medicine |
Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002303262A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene shinc-1 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
*
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
*
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
KR100788092B1
(ko)
|
2001-06-20 |
2007-12-21 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
DE60238143D1
(de)
|
2001-09-18 |
2010-12-09 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ585001A
(en)
|
2001-10-09 |
2011-08-26 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US20030224380A1
(en)
*
|
2001-10-25 |
2003-12-04 |
The General Hospital Corporation |
Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
|
AU2002364945A1
(en)
*
|
2001-10-25 |
2003-07-09 |
Neurogenetics, Inc. |
Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
|
US20030170678A1
(en)
*
|
2001-10-25 |
2003-09-11 |
Neurogenetics, Inc. |
Genetic markers for Alzheimer's disease and methods using the same
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
MXPA04006554A
(es)
|
2002-01-02 |
2005-03-31 |
Genentech Inc |
Composiciones y metodos para diagnostico y tratamiento de tumor.
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
WO2003062404A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Gamida-Cell Ltd. |
Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
|
US7244565B2
(en)
*
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
*
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
EP2011886A3
(de)
|
2002-04-16 |
2009-02-11 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
AU2003228809A1
(en)
*
|
2002-05-03 |
2003-11-17 |
Sequenom, Inc. |
Kinase anchor protein muteins, peptides thereof, and related methods
|
US20030228317A1
(en)
*
|
2002-05-22 |
2003-12-11 |
Prafulla Gokhale |
Gene BRCC-1 and diagnostic and therapeutic uses thereof
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
AU2003231912A1
(en)
*
|
2002-06-12 |
2003-12-31 |
Tel Aviv Medical Center Research Development Fund |
Methods of detecting and treating prostate cancer
|
CA2491034A1
(en)
*
|
2002-06-26 |
2004-01-08 |
The Penn State Research Foundation |
Methods and materials for treating human papillomavirus infections
|
US6889143B2
(en)
*
|
2002-09-12 |
2005-05-03 |
Intergrated Dna Technologies, Inc. |
Methods and systems for estimating the melting temperature (TM) for polynucleotide molecules
|
EP2272958A1
(de)
|
2002-09-26 |
2011-01-12 |
ISIS Pharmaceuticals, Inc. |
Modulierung von der Forkheadbox O1A-Expression
|
EP1560597A4
(de)
*
|
2002-10-29 |
2007-06-27 |
Pharmacia Corp |
Differentiell ausgedrückte krebsgene, dabei kodierte polypeptide und verfahren zu ihrer verwendung
|
US9150606B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
US8604183B2
(en)
*
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
US9150605B2
(en)
*
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
SI1569695T1
(sl)
|
2002-11-13 |
2013-08-30 |
Genzyme Corporation |
Protismiselna modulacija ekspresije apolipoproteina B
|
WO2004046330A2
(en)
|
2002-11-15 |
2004-06-03 |
Morphotek, Inc. |
Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
EP1597366B1
(de)
|
2003-02-11 |
2012-11-21 |
Antisense Therapeutics Ltd |
Modulation der expression des insulinähnlichen wachstumsfaktor i-rezeptors
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20070141570A1
(en)
*
|
2003-03-07 |
2007-06-21 |
Sequenom, Inc. |
Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
EP2241572A3
(de)
|
2003-06-03 |
2011-04-06 |
Eli Lilly And Company |
Modulation d'expression de survivine
|
US8008265B2
(en)
|
2003-06-13 |
2011-08-30 |
The Trustees Of The University Of Pennsylvania |
Vaccines, immunotherapeutics and methods for using the same
|
EP1644475A4
(de)
*
|
2003-06-20 |
2009-06-03 |
Isis Pharmaceuticals Inc |
Doppelstrang-zusammensetzungen mit einem 3'-endo-modifizierten strang zur verwendung bei der genmodulation
|
US20060241072A1
(en)
*
|
2003-06-20 |
2006-10-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds for use in gene modulation
|
AU2004257167B2
(en)
|
2003-07-03 |
2012-03-29 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20050053981A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
CA2538252C
(en)
*
|
2003-09-18 |
2014-02-25 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
EP2256201A3
(de)
|
2003-09-18 |
2012-07-04 |
Isis Pharmaceuticals, Inc. |
Modulation der eIF4E expression
|
DK1678194T3
(da)
|
2003-10-10 |
2013-10-07 |
Alchemia Oncology Pty Ltd |
Modulering af syntese og degradering af hyaluronan i behandlingen af sygdom
|
KR20060116825A
(ko)
|
2003-10-23 |
2006-11-15 |
일루미겐 바이오사이언시스, 인코포레이티드 |
바이러스 감염에 대한 저항성과 관련된 유전자인oas1에서의 돌연변이의 검출
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
EP2412725A3
(de)
|
2003-11-17 |
2012-04-25 |
Genentech, Inc. |
Antikörper gegen CD79b zur Behandlung von Tumoren hämatopoetischen Ursprungs
|
US20050120397A1
(en)
*
|
2003-11-24 |
2005-06-02 |
Hermann Steller |
Compounds and methods for regulation of spermatid differentiation
|
US7695932B2
(en)
*
|
2003-12-24 |
2010-04-13 |
Massachusetts Institute Of Technology |
Gene targets for enhanced carotenoid production
|
US7741070B2
(en)
*
|
2003-12-24 |
2010-06-22 |
Massachusetts Institute Of Technology |
Gene targets for enhanced carotenoid production
|
US7608699B2
(en)
*
|
2003-12-29 |
2009-10-27 |
Rockefeller University |
Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US20070269889A1
(en)
*
|
2004-02-06 |
2007-11-22 |
Dharmacon, Inc. |
Stabilized siRNAs as transfection controls and silencing reagents
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
WO2005089268A2
(en)
|
2004-03-15 |
2005-09-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of rna by rnase h
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
AU2005230684B2
(en)
|
2004-04-05 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US20080261904A1
(en)
*
|
2004-06-03 |
2008-10-23 |
Balkrishen Bhat |
Chimeric Gapped Oligomeric Compounds
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US8680062B2
(en)
|
2004-07-06 |
2014-03-25 |
Deliversir Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
PT1786472E
(pt)
|
2004-08-10 |
2013-03-06 |
Genzyme Corp |
Modulação anti-sentido de expressão de apolipoproteína
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP1799812A4
(de)
*
|
2004-09-16 |
2009-09-09 |
Gamida Cell Ltd |
Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
|
WO2006034348A2
(en)
|
2004-09-17 |
2006-03-30 |
Isis Pharmaceuticals, Inc. |
Enhanced antisense oligonucleotides
|
NZ554277A
(en)
|
2004-10-20 |
2010-09-30 |
Antisense Therapeutics Ltd |
Antisense modulation of integrin alpha 4 expression
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
US7923206B2
(en)
*
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Method of determining a cellular response to a biological agent
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
JP2008535796A
(ja)
|
2005-03-10 |
2008-09-04 |
ジェネンテック・インコーポレーテッド |
脈管の完全性を調節するための方法及び組成物
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
CA2606270A1
(en)
*
|
2005-04-19 |
2006-10-26 |
Massachusetts Institute Of Technology |
Amphiphilic polymers and methods of use thereof
|
AU2006243218B2
(en)
|
2005-05-05 |
2009-09-17 |
Antisense Pharma Gmbh |
Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors
|
WO2007008300A2
(en)
|
2005-05-31 |
2007-01-18 |
ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
WO2006138145A1
(en)
|
2005-06-14 |
2006-12-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
WO2007062380A2
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
EP1976567B1
(de)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
|
EP3210633B1
(de)
|
2006-01-26 |
2019-06-19 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und deren verwendungen in bezug auf huntingtin
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
DK2314594T3
(da)
*
|
2006-01-27 |
2014-10-27 |
Isis Pharmaceuticals Inc |
6-modificerede bicykliske nukleinsyreanaloger
|
AU2007211082B2
(en)
|
2006-01-27 |
2012-09-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of microRNAs
|
CA3044969A1
(en)
*
|
2006-05-05 |
2007-12-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gene expression
|
CA2651453C
(en)
|
2006-05-11 |
2014-10-14 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
US7666854B2
(en)
*
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
EP2023938A4
(de)
*
|
2006-05-23 |
2010-11-10 |
Isis Pharmaceuticals Inc |
Modulation von chrebp-expression
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
EP2061515A4
(de)
|
2006-09-14 |
2013-01-30 |
Medgenics Medical Israel Ltd |
Heilmittelformulierungen mit langzeitwirkung
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
WO2008036825A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
EP1935428A1
(de)
*
|
2006-12-22 |
2008-06-25 |
Antisense Pharma GmbH |
Oligonukleotid-Polymer Konjugate
|
US8507200B2
(en)
*
|
2007-02-09 |
2013-08-13 |
Northwestern University |
Particles for detecting intracellular targets
|
US9156865B2
(en)
|
2007-04-23 |
2015-10-13 |
Deliversir Ltd |
System for delivering therapeutic agents into living cells and cells nuclei
|
US9556210B2
(en)
|
2007-04-23 |
2017-01-31 |
Sabag-Rfa Ltd. |
System for delivering therapeutic agents into living cells and cells nuclei
|
WO2014064687A1
(en)
|
2012-10-22 |
2014-05-01 |
Deliversir Ltd |
A system for delivering therapeutic agents into living cells and cells nuclei
|
WO2008129548A2
(en)
*
|
2007-04-23 |
2008-10-30 |
Segev Laboratories Limited |
A system for delivering therapeutic agents into living cells and cells nuclei
|
EP2170917B1
(de)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
Über n-substituiertes aminomethylen verbrückte, bicyclische nukleinsäureanaloga
|
WO2008151049A2
(en)
|
2007-05-30 |
2008-12-11 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
WO2008154401A2
(en)
|
2007-06-08 |
2008-12-18 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
CA2692579C
(en)
*
|
2007-07-05 |
2016-05-03 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
KR101654007B1
(ko)
|
2007-08-15 |
2016-09-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
테트라하이드로피란 핵산 유사체
|
WO2009039442A1
(en)
*
|
2007-09-21 |
2009-03-26 |
California Institute Of Technology |
Nfia in glial fate determination, glioma therapy and astrocytoma treatment
|
US20100280098A1
(en)
*
|
2007-10-05 |
2010-11-04 |
Juliano Rudolph L |
Receptor targeted oligonucleotides
|
EP2219680A2
(de)
|
2007-11-13 |
2010-08-25 |
Isis Pharmaceuticals, Inc. |
Verbindungen und verfahren zur modulation der proteinexpression
|
USRE47320E1
(en)
|
2007-11-20 |
2019-03-26 |
Ionis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
US8546556B2
(en)
*
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
US7845686B2
(en)
*
|
2007-12-17 |
2010-12-07 |
S & B Technical Products, Inc. |
Restrained pipe joining system for plastic pipe
|
EP2265627A2
(de)
*
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexitolnukleinsäureanaloga
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
WO2009117589A1
(en)
|
2008-03-21 |
2009-09-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
EP2285819B1
(de)
*
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
|
US8082730B2
(en)
*
|
2008-05-20 |
2011-12-27 |
Caterpillar Inc. |
Engine system having particulate reduction device and method
|
JP2011529708A
(ja)
|
2008-08-04 |
2011-12-15 |
ユニバーシティ オブ マイアミ |
自然免疫応答の調節因子sting(インターフェロン遺伝子の刺激因子)
|
EP2323667A4
(de)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
|
EP3081648A1
(de)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
|
US8796443B2
(en)
|
2008-09-22 |
2014-08-05 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
EP2356129B1
(de)
*
|
2008-09-24 |
2013-04-03 |
Isis Pharmaceuticals, Inc. |
Substituierte alpha-l-bicyclische nukleoside
|
WO2010036696A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Cyclohexenyl nucleic acid analogs
|
AU2009305636A1
(en)
|
2008-10-15 |
2010-04-22 |
Ionis Pharmaceuticals, Inc. |
Modulation of Factor 11 expression
|
US8987435B2
(en)
|
2008-10-24 |
2015-03-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
CA2741294C
(en)
|
2008-10-24 |
2018-04-24 |
Isis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
MX2011005429A
(es)
*
|
2008-11-24 |
2011-06-21 |
Univ Northwestern |
Composiciones de nanoparticulas de arn polivalentes.
|
EP2370580B1
(de)
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirtuin 1
|
RU2746478C2
(ru)
|
2008-12-04 |
2021-04-14 |
КьюРНА, Инк. |
Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
EP2376633A1
(de)
|
2008-12-17 |
2011-10-19 |
AVI BioPharma, Inc. |
Antisense-zusammensetzungen und verfahren zur modulation von kontaktüberempfindlichkeit oder kontaktdermatitis
|
US20100233270A1
(en)
*
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
US20100184844A1
(en)
*
|
2009-01-08 |
2010-07-22 |
Northwestern University |
Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
|
KR101546673B1
(ko)
*
|
2009-01-15 |
2015-08-25 |
삼성전자주식회사 |
전자 사진용 토너 및 그의 제조방법
|
US20120021515A1
(en)
|
2009-02-06 |
2012-01-26 |
Swayze Eric E |
Oligomeric compounds and methods
|
US8536320B2
(en)
|
2009-02-06 |
2013-09-17 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
PT2396038E
(pt)
|
2009-02-12 |
2016-02-19 |
Curna Inc |
Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
CA2754749C
(en)
|
2009-03-04 |
2019-04-30 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
ES2656290T3
(es)
|
2009-03-16 |
2018-02-26 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
|
EP2408920B1
(de)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
CA2760589C
(en)
|
2009-05-01 |
2019-08-20 |
Joseph Collard |
Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ttp에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
CA2762369C
(en)
|
2009-05-18 |
2021-12-28 |
Joseph Collard |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
EP2432882B1
(de)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
EP2443237B1
(de)
|
2009-06-16 |
2017-02-22 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem kollagengen durch hemmung des natürlichen antisense-transkripts zu einem kollagengens
|
CN102597238B
(zh)
|
2009-06-24 |
2016-06-29 |
库尔纳公司 |
通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
EP2462153B1
(de)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclische cyclohexosenukleinsäureanaloga
|
JP5964232B2
(ja)
|
2009-08-25 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
US8664377B2
(en)
*
|
2009-09-30 |
2014-03-04 |
Samsung Electronics Co., Ltd. |
Method and apparatus for isolating nucleic acids
|
RU2539772C2
(ru)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
|
EP2494075B1
(de)
|
2009-10-30 |
2018-04-04 |
Northwestern University |
Templatgesteuerte nanokonjugate
|
KR101944119B1
(ko)
|
2009-11-13 |
2019-01-30 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 항바이러스 화합물 및 인플루엔자 바이러스 감염을 치료하는 방법
|
CN103755809B
(zh)
|
2009-11-30 |
2016-06-01 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
KR101823702B1
(ko)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
JP6031356B2
(ja)
|
2009-12-23 |
2016-11-24 |
カッパーアールエヌエー,インコーポレイテッド |
Ucp2に対する天然アンチセンス転写産物の阻害による脱共役タンパク質2(ucp2)関連疾患の治療
|
CN102782134B
(zh)
|
2009-12-29 |
2017-11-24 |
库尔纳公司 |
通过抑制核呼吸因子1(nrf1)的天然反义转录物而治疗nrf1相关疾病
|
CA2785177C
(en)
|
2009-12-29 |
2019-09-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
WO2011082409A2
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
EP2524039B1
(de)
|
2010-01-11 |
2017-11-29 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem sexualhormonbindenden globulin (shgb) mittels hemmung des natürlichen antisense-transkripts gegen shbg
|
US8779118B2
(en)
|
2010-01-11 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
RU2611192C2
(ru)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
US9068185B2
(en)
|
2010-03-12 |
2015-06-30 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
EP2544703A4
(de)
|
2010-03-12 |
2013-09-18 |
Brigham & Womens Hospital |
Verfahren zur behandlung von gefässentzündungserkrankungen
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US20120108799A1
(en)
|
2010-09-07 |
2012-05-03 |
Integrated Dna Technologies, Inc. |
Modifications for Antisense Compounds
|
US9506057B2
(en)
|
2010-03-26 |
2016-11-29 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
TWI644675B
(zh)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病
|
EP2563380B1
(de)
|
2010-04-26 |
2018-05-30 |
aTyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten der cysteinyl-trna-synthetase
|
AU2011248614B2
(en)
|
2010-04-27 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
US8993723B2
(en)
|
2010-04-28 |
2015-03-31 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
|
WO2011139699A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
US8993738B2
(en)
|
2010-04-28 |
2015-03-31 |
Isis Pharmaceuticals, Inc. |
Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
|
EP2563383B1
(de)
|
2010-04-29 |
2017-03-01 |
Atyr Pharma, Inc. |
Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
BR112012027547B1
(pt)
|
2010-04-29 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
|
WO2011139986A2
(en)
|
2010-05-03 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
KR101915115B1
(ko)
|
2010-05-03 |
2018-11-05 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
CN103140233B
(zh)
|
2010-05-03 |
2017-04-05 |
Atyr 医药公司 |
与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
|
ES2623805T3
(es)
|
2010-05-03 |
2017-07-12 |
Atyr Pharma, Inc. |
Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
|
JP6008844B2
(ja)
|
2010-05-04 |
2016-10-19 |
エータイアー ファーマ, インコーポレイテッド |
p38MULTI−tRNA合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
JP5866106B2
(ja)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
インスリンを産生し分泌する腸内分泌細胞の製造方法
|
CA3090304A1
(en)
|
2010-05-13 |
2011-11-17 |
Sarepta Therapeutics, Inc. |
Antisense modulation of interleukins 17 and 23 signaling
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
AU2011252990B2
(en)
|
2010-05-14 |
2017-04-20 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
CA2799480C
(en)
|
2010-05-17 |
2020-12-15 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
EP2575856B1
(de)
|
2010-05-27 |
2017-08-16 |
aTyr Pharma, Inc. |
Therapeutische, diagnostische und antikörperhaltige zusammensetzungen in zusammenhang mit proteinfragmenten von glutaminyl-trna-synthetasen
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
US8846637B2
(en)
|
2010-06-08 |
2014-09-30 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2011159758A2
(en)
|
2010-06-15 |
2011-12-22 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
WO2012021247A2
(en)
|
2010-07-12 |
2012-02-16 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
CN103210086B
(zh)
|
2010-10-06 |
2017-06-09 |
库尔纳公司 |
通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
|
CN103517990A
(zh)
|
2010-10-07 |
2014-01-15 |
通用医疗公司 |
癌症生物标志物
|
EP2630241B1
(de)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Behandlung von alpha-l-iduronidase (idua)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen idua
|
JP6073795B2
(ja)
|
2010-10-27 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
インターフェロン関連発生制御因子1(ifrd1)への天然アンチセンス転写物の阻害によるifrd1関連疾患の治療
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
EP2453017A1
(de)
|
2010-11-12 |
2012-05-16 |
Antisense Pharma GmbH |
Oligonucleotide zur Verwendung bei der Prophilaxe und/oder Behandlung von TGF-beta1- und TGF-beta2-, TGF-beta2- und TGF-beta3-, TGF-beta1- und TGF-beta3- oder TGF-beta1-, TGF-beta2- und TGF-beta3-mRNA-Überexpressionskrankheiten
|
EP2638163B1
(de)
|
2010-11-12 |
2017-05-17 |
The General Hospital Corporation |
Polycomb-assoziierte nicht-kodierende rnas
|
AU2011329777B2
(en)
|
2010-11-17 |
2016-06-09 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
US9045749B2
(en)
|
2011-01-14 |
2015-06-02 |
The General Hospital Corporation |
Methods targeting miR-128 for regulating cholesterol/lipid metabolism
|
EP2668199B1
(de)
|
2011-01-27 |
2017-09-06 |
Ramot at Tel Aviv University, Ltd. |
Glycogensynthasekinase-3-inhibitoren
|
US9688719B2
(en)
|
2011-01-27 |
2017-06-27 |
Ramot At Tel-Aviv University Ltd. |
Glycogen synthase kinase-3 inhibitors
|
EP2670404B1
(de)
|
2011-02-02 |
2018-08-29 |
The Trustees of Princeton University |
Sirtuin-modulatoren als modulatoren der virusproduktion
|
KR101697396B1
(ko)
|
2011-02-02 |
2017-01-17 |
엑스칼리아드 파마슈티컬즈, 인코포레이티드 |
결합 조직 성장 인자(ctgf)를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법
|
CA2838588C
(en)
|
2011-06-09 |
2021-09-14 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
WO2012170347A1
(en)
|
2011-06-09 |
2012-12-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
JP6129844B2
(ja)
|
2011-09-14 |
2017-05-17 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
CA2847698C
(en)
|
2011-09-14 |
2020-09-01 |
Northwestern University |
Nanoconjugates able to cross the blood-brain barrier
|
AU2012322788B2
(en)
|
2011-10-11 |
2018-01-04 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
SG11201404608WA
(en)
|
2012-02-13 |
2014-09-26 |
Gamida Cell Ltd |
Mesenchymal stem cells conditioned medium and methods of generating and using the same
|
KR20140136488A
(ko)
|
2012-03-15 |
2014-11-28 |
큐알엔에이, 인크. |
뇌 유래 신경영양 인자(bdnf)에 대한 천연 안티센스 전사체의 저해에 의한 뇌 유래 신경영양 인자(bdnf)관련 질환의 치료
|
WO2013138662A1
(en)
|
2012-03-16 |
2013-09-19 |
4S3 Bioscience, Inc. |
Antisense conjugates for decreasing expression of dmpk
|
US9221864B2
(en)
|
2012-04-09 |
2015-12-29 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
WO2013154799A1
(en)
|
2012-04-09 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Tricyclic nucleosides and oligomeric compounds prepared therefrom
|
AU2013248981B2
(en)
|
2012-04-20 |
2018-11-29 |
Aptamir Therapeutics, Inc. |
Mirna modulators of thermogenesis
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
KR102028784B1
(ko)
|
2012-05-16 |
2019-10-04 |
트랜슬레이트 바이오 인코포레이티드 |
유전자 발현을 조절하기 위한 조성물 및 방법
|
CA2873766A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating atp2a2 expression
|
CN104583399A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节血红蛋白基因家族表达的组合物和方法
|
CN104583402A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节mecp2表达的组合物和方法
|
WO2013173645A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating utrn expression
|
WO2013184209A1
(en)
|
2012-06-04 |
2013-12-12 |
Ludwig Institute For Cancer Research Ltd. |
Mif for use in methods of treating subjects with a neurodegenerative disorder
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
CA2880833A1
(en)
|
2012-08-03 |
2014-02-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
KR102237882B1
(ko)
|
2012-08-15 |
2021-04-07 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
WO2014130945A1
(en)
|
2013-02-25 |
2014-08-28 |
Integrated Dna Technologies, Inc. |
Modifications for antisense compounds
|
EP3633039A1
(de)
|
2013-05-01 |
2020-04-08 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren
|
WO2014197938A1
(en)
|
2013-06-13 |
2014-12-18 |
Antisense Therapeutics Ltd |
Combination therapy
|
WO2014207743A2
(en)
|
2013-06-24 |
2014-12-31 |
Ramot At Tel-Aviv University Ltd. |
Glycogen synthase kinase-3 inhibitors
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
HUE052814T2
(hu)
|
2014-01-31 |
2021-05-28 |
Temple Univ Of The Commonwealth System |
A szívelégtelenség terápiájához célfehérjeként alkamazott BAG3
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015142910A1
(en)
|
2014-03-17 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
|
CA2942340A1
(en)
|
2014-03-19 |
2015-09-24 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
SG10201906520RA
(en)
|
2014-04-01 |
2019-09-27 |
Biogen Ma Inc |
Compositions for modulating sod-1 expression
|
WO2015164693A1
(en)
|
2014-04-24 |
2015-10-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising alpha-beta-constrained nucleic acid
|
PE20170010A1
(es)
|
2014-05-01 |
2017-03-04 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion del factor b del complemento
|
TR201908550T4
(tr)
|
2014-06-04 |
2019-07-22 |
Exicure Inc |
Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
|
CN106661580B
(zh)
|
2014-06-10 |
2022-02-15 |
鹿特丹伊拉斯谟大学医疗中心 |
用于治疗庞帕病的反义寡核苷酸
|
WO2015200697A1
(en)
|
2014-06-25 |
2015-12-30 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
US10487314B2
(en)
|
2014-06-26 |
2019-11-26 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
EP3198012B1
(de)
|
2014-09-26 |
2019-09-04 |
University of Massachusetts |
Rna-modulierende stoffe
|
EP3212824A4
(de)
|
2014-10-30 |
2018-08-08 |
The General Hospital Corporation |
Verfahren zur modulierung einer atrx-abhängigen genunterdrückung
|
CN107106493A
(zh)
|
2014-11-21 |
2017-08-29 |
西北大学 |
球形核酸纳米颗粒缀合物的序列特异性细胞摄取
|
US9688707B2
(en)
|
2014-12-30 |
2017-06-27 |
Ionis Pharmaceuticals, Inc. |
Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
WO2016164463A1
(en)
|
2015-04-07 |
2016-10-13 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive x chromosome
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
CA2990852A1
(en)
|
2015-06-26 |
2016-12-29 |
Beth Israel Deaconess Medical Center, Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
CA2991045A1
(en)
|
2015-06-29 |
2017-01-05 |
Caris Science, Inc. |
Therapeutic oligonucleotides binding c1q
|
WO2017019918A1
(en)
|
2015-07-28 |
2017-02-02 |
Caris Science, Inc. |
Targeted oligonucleotides
|
EP3353303B1
(de)
|
2015-09-25 |
2023-08-02 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
|
AU2016349954B2
(en)
|
2015-11-05 |
2022-08-25 |
Antisense Therapeutics Ltd |
Mobilizing leukemia cells
|
US11001622B2
(en)
|
2015-11-19 |
2021-05-11 |
The Brigham And Women's Hospital, Inc. |
Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
|
EP3389670A4
(de)
|
2015-12-04 |
2020-01-08 |
Ionis Pharmaceuticals, Inc. |
Verfahren zur behandlung von brustkrebs
|
US10993995B2
(en)
|
2015-12-07 |
2021-05-04 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
WO2017147087A1
(en)
|
2016-02-25 |
2017-08-31 |
The Brigham And Women's Hospital, Inc. |
Treatment methods for fibrosis targeting smoc2
|
CA3013799A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating keap1
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
CN109715802A
(zh)
|
2016-03-18 |
2019-05-03 |
卡里斯科学公司 |
寡核苷酸探针及其用途
|
WO2017205686A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
US11236339B2
(en)
|
2016-06-17 |
2022-02-01 |
Ionis Pharmaceuticals, Inc. |
Modulation of GYS1 expression
|
US11253601B2
(en)
|
2016-07-11 |
2022-02-22 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
EP3522898A4
(de)
|
2016-10-06 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
Verfahren zum konjugieren von oligomeren verbindungen
|
CA3037046A1
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
WO2018165564A1
(en)
|
2017-03-09 |
2018-09-13 |
Ionis Pharmaceuticals, Inc. |
Morpholino modified oligomeric compounds
|
AU2018256435A1
(en)
|
2017-04-20 |
2019-11-07 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
MA51645A
(fr)
|
2018-01-15 |
2020-11-25 |
Ionis Pharmaceuticals Inc |
Modulateurs de l'expression de dnm2
|
US11732260B2
(en)
|
2018-03-02 |
2023-08-22 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of amyloid-β precursor protein
|
WO2019169219A1
(en)
|
2018-03-02 |
2019-09-06 |
Ionis Pharmaceuticals, Inc. |
Modulators of irf4 expression
|
WO2019183440A1
(en)
|
2018-03-22 |
2019-09-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating fmr1 expression
|
CA3095545A1
(en)
|
2018-03-30 |
2019-10-03 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
EP3772928A4
(de)
|
2018-04-06 |
2021-12-29 |
Children's Medical Center Corporation |
Zusammensetzungen und verfahren zur prägung der umprogrammierung und modulation von somatischen zellen
|
US11365416B2
(en)
|
2018-04-11 |
2022-06-21 |
Ionis Pharmaceuticals, Inc. |
Modulators of EZH2 expression
|
BR112020020957B1
(pt)
|
2018-05-09 |
2022-05-10 |
Ionis Pharmaceuticals, Inc |
Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
|
PE20212131A1
(es)
|
2018-05-09 |
2021-11-05 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para reducir de la expresion de atxn3
|
JP2021526823A
(ja)
|
2018-06-14 |
2021-10-11 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Stmn2発現を増加させるための化合物及び方法
|
AU2019294838A1
(en)
|
2018-06-27 |
2021-01-07 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing LRRK2 expression
|
JP2021531252A
(ja)
|
2018-07-02 |
2021-11-18 |
アプタミアール セラピューティクス インコーポレイテッド |
ヒト脂肪細胞への治療薬の標的化送達
|
US11078486B2
(en)
|
2018-07-25 |
2021-08-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing ATXN2 expression
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
MX2021005758A
(es)
|
2018-11-15 |
2021-09-21 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresión de irf5.
|
US11214803B2
(en)
|
2019-01-31 |
2022-01-04 |
Ionis Pharmaceuticals, Inc. |
Modulators of YAP1 expression
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
WO2020176771A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
CN113728104B
(zh)
|
2019-03-29 |
2023-10-27 |
Ionis制药公司 |
用于调节ube3a-ats的化合物和方法
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
WO2021030778A1
(en)
|
2019-08-15 |
2021-02-18 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds and uses thereof
|
KR20220148230A
(ko)
|
2020-02-28 |
2022-11-04 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Smn2를 조절하기 위한 화합물 및 방법
|
JP2023524065A
(ja)
|
2020-05-01 |
2023-06-08 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Atxn1を調節するための化合物及び方法
|
MX2022016338A
(es)
|
2020-06-29 |
2023-01-24 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la plp1.
|
JP2023549563A
(ja)
|
2020-11-18 |
2023-11-27 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
アンジオテンシノーゲン発現を調節するための化合物及び方法
|
BR112023026050A2
(pt)
|
2021-06-18 |
2024-03-05 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para reduzir expressão de ifnar1
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024044352A1
(en)
|
2022-08-26 |
2024-02-29 |
The General Hospital Corporation |
Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
|